Literature DB >> 20671587

Macular telangiectasia: patterns of distribution of macular pigment and response to supplementation.

Meike B Zeimer1, Isabel Krömer, Georg Spital, Albrecht Lommatzsch, Daniel Pauleikhoff.   

Abstract

PURPOSE: By analyzing the patterns of macular pigment (MP) in type 2 idiopathic telangiectasia eyes, different stages in the changes reflecting the extent of disease can be observed. The purpose of this study was to determine whether the amount and the pattern of MP can be influenced by supplementation.
METHOD: Eleven patients with type 2 idiopathic telangiectasia received 12 mg lutein and 0.6 mg zeaxanthin (Ocuvite Lutein AMD) daily for 9 months. For a period of 12 months, MP concentration was determined every 3 months by autofluorescence (2 excitation wavelengths: 488 and 514 nm).
RESULTS: When central accumulation of MP was similar to that in healthy subjects (with segment of reduced MP in the temporal fovea: MP Class I), supplementation enriched the MP at 0.5 degrees, 2 degrees, and 5 degrees to 6 degrees. In MP Class II (reduced concentration of MP centrally), accumulation could be detected at 2 degrees and 5 degrees to 6 degrees but not centrally. In MP Class III (oval-shaped effacement of MP centrally, surrounding oval-shaped ring of MP at 5 degrees-7 degrees eccentricity), supplementation promoted MP accumulation only at 5 degrees to 6 degrees.
CONCLUSION: After oral supplementation with lutein/zeaxanthin, an increase in the MP was detected only in areas where the MP was present at baseline. Supplementation did not produce an increase in the area where the MP was absent. Degenerative processes causing an impairment in transport and storage of lutein and zeaxanthin may play a leading role in the pathogenesis of type 2 idiopathic telangiectasia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20671587     DOI: 10.1097/IAE.0b013e3181e096dd

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  13 in total

1.  REPRODUCIBILITY OF MACULAR PIGMENT OPTICAL DENSITY MEASUREMENT BY TWO-WAVELENGTH AUTOFLUORESCENCE IN A CLINICAL SETTING.

Authors:  Qi Sheng You; Dirk-Uwe G Bartsch; Mark Espina; Mostafa Alam; Natalia Camacho; Nadia Mendoza; William R Freeman
Journal:  Retina       Date:  2016-07       Impact factor: 4.256

Review 2.  Macular telangiectasia type 2.

Authors:  Peter Charbel Issa; Mark C Gillies; Emily Y Chew; Alan C Bird; Tjebo F C Heeren; Tunde Peto; Frank G Holz; Hendrik P N Scholl
Journal:  Prog Retin Eye Res       Date:  2012-12-03       Impact factor: 21.198

3.  [Therapeutic approaches for macular telangiectasia type 2: status quo and perspectives].

Authors:  F G Holz; T F C Heeren; E Krüger; M Zeimer; D Pauleikhoff; P Charbel Issa
Journal:  Ophthalmologe       Date:  2014-09       Impact factor: 1.059

4.  Global Connections to Study Idiopathic Macular Telangiectasia Type 2.

Authors:  Emily Y Chew; Martin Friedlander
Journal:  Retina       Date:  2018-01       Impact factor: 4.256

Review 5.  Lutein, zeaxanthin, and meso-zeaxanthin: The basic and clinical science underlying carotenoid-based nutritional interventions against ocular disease.

Authors:  Paul S Bernstein; Binxing Li; Preejith P Vachali; Aruna Gorusupudi; Rajalekshmy Shyam; Bradley S Henriksen; John M Nolan
Journal:  Prog Retin Eye Res       Date:  2015-11-02       Impact factor: 21.198

6.  MACULAR PIGMENT DISTRIBUTION RESPONSES TO HIGH-DOSE ZEAXANTHIN SUPPLEMENTATION IN PATIENTS WITH MACULAR TELANGIECTASIA TYPE 2.

Authors:  Rene Y Choi; Aruna Gorusupudi; Kimberley Wegner; Mohsen Sharifzadeh; Werner Gellermann; Paul S Bernstein
Journal:  Retina       Date:  2017-12       Impact factor: 4.256

7.  Outcome of Off-Label AREDS 2 Supplementation for the Treatment of Macular Degeneration in Non-Proliferative Idiopathic Type 2 Macular Telangiectasia.

Authors:  Tyler A Berger; Matthew W Manry; Lucas B Lindsell; James M Osher; Daniel M Miller; Robert E Foster; Christopher D Riemann; Michael R Petersen; Robert A Sisk
Journal:  Clin Ophthalmol       Date:  2021-03-15

8.  Changes of macular pigment optical density in elderly eyes: a longitudinal analysis from the MARS study.

Authors:  Verena Meyer Zu Westrup; Martha Dietzel; Meike Zeimer; Daniel Pauleikhoff; Hans-Werner Hense
Journal:  Int J Retina Vitreous       Date:  2016-06-01

Review 9.  When is macular edema not macular edema? An update on macular telangiectasia type 2.

Authors:  Lihteh Wu
Journal:  Taiwan J Ophthalmol       Date:  2015-11-14

Review 10.  Why is Zeaxanthin the Most Concentrated Xanthophyll in the Central Fovea?

Authors:  Justyna Widomska; John Paul SanGiovanni; Witold K Subczynski
Journal:  Nutrients       Date:  2020-05-07       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.